Search Results - "Dansin, Eric"

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients by Delaunay, Myriam, Cadranel, Jacques, Lusque, Amélie, Meyer, Nicolas, Gounant, Valérie, Moro-Sibilot, Denis, Michot, Jean-Marie, Raimbourg, Judith, Girard, Nicolas, Guisier, Florian, Planchard, David, Metivier, Anne-Cécile, Tomasini, Pascale, Dansin, Eric, Pérol, Maurice, Campana, Marion, Gautschi, Oliver, Früh, Martin, Fumet, Jean-David, Audigier-Valette, Clarisse, Couraud, Sébastien, Dalle, Stéphane, Leccia, Marie-Thérèse, Jaffro, Marion, Collot, Samia, Prévot, Grégoire, Milia, Julie, Mazieres, Julien

“…Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung…”
Get full text

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives by Mazières, Julien, Peters, Solange, Lepage, Benoit, Cortot, Alexis B., Barlesi, Fabrice, Beau-Faller, Michéle, Besse, Benjamin, Blons, Hélène, Mansuet-Lupo, Audrey, Urban, Thierry, Moro-Sibilot, Denis, Dansin, Eric, Chouaid, Christos, Wislez, Marie, Diebold, Joachim, Felip, Enriqueta, Rouquette, Isabelle, Milia, Julie D., Gautschi, Oliver

“…HER2 mutations are identified in approximately 2%of non-small-cell lung cancers (NSCLC). There are few data available that describe the clinical course of…”
Get full text

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study by Crinò, Lucio, Prof, Dansin, Eric, MD, Garrido, Pilar, MD, Griesinger, Frank, Prof, Laskin, Janessa, MD, Pavlakis, Nick, MBBS, Stroiakovski, Daniel, Prof, Thatcher, Nick, Prof, Tsai, Chun-Ming, Prof, Wu, Yi-long, Prof, Zhou, Caicun, Prof

“…Summary Background Results of two phase 3 trials have shown first-line bevacizumab in combination with chemotherapy improves clinical outcomes in patients with…”
Get full text

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial by Quoix, Elisabeth, Prof, Zalcman, Gérard, Prof, Oster, Jean-Philippe, MD, Westeel, Virginie, Prof, Pichon, Eric, MD, Lavolé, Armelle, MD, Dauba, Jérôme, MD, Debieuvre, Didier, MD, Souquet, Pierre-Jean, MD, Bigay-Game, Laurence, MD, Dansin, Eric, MD, Poudenx, Michel, MD, Molinier, Olivier, MD, Vaylet, Fabien, MD, Moro-Sibilot, Denis, Prof, Herman, Dominique, MD, Bennouna, Jaafar, MD, Tredaniel, Jean, Prof, Ducoloné, Alain, MD, Lebitasy, Marie-Paule, MD, Baudrin, Laurence, MSc, Laporte, Silvy, PhD, Milleron, Bernard, MD

“…Summary Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but…”
Get full text

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer by Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, De Petris, Luigi, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C, Crino, Lucio, Lena, Herve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N, Zeaiter, Ali, Shaw, Alice T

“…Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and…”
Get more information

Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique–Groupe Français de Pneumo-Cancérologie NPC 95-01 Study by Fournel, Pierre, Robinet, Gilles, Thomas, Pascal, Souquet, Pierre-Jean, Léna, Hervé, Vergnenégre, Alain, Delhoume, Jean-Yves, Le Treut, Jacques, Silvani, Jules-Antoine, Dansin, Eric, Bozonnat, Marie-Cécile, Daurés, Jean-Pierre, Mornex, Françoise, Pérol, Maurice

“…We conducted a phase III study to compare the survival impact of concurrent versus sequential treatment with radiotherapy (RT) and chemotherapy (CT) in…”
Get full text

Image-guided robotic stereotactic radiation therapy with fiducial-free tumor tracking for lung cancer by Bibault, Jean-Emmanuel, Prevost, Bernard, Dansin, Eric, Mirabel, Xavier, Lacornerie, Thomas, Lartigau, Eric

“…Stereotactic body radiation therapy (SBRT) for early-stage lung cancer can be achieved with several methods: respiratory gating, body frame, or real-time…”
Get full text

A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes by Chouaid, Christos, Filleron, Thomas, Debieuvre, Didier, Pérol, Maurice, Girard, Nicolas, Dansin, Eric, Lena, Hervé, Gervais, Radj, Cousin, Sophie, Otto, Josiane, Schott, Roland, Planchard, David, Madroszyk, Anne, Kaderbhai, Courèche, DUBRAY-Longeras, Pascale, Hiret, Sandrine, Pichon, Eric, Clément-Duchêne, Christelle, Chenuc, Gaëlle, Simon, Gaëtane, Bosquet, Lise, QUantin, Xavier

“…Background In Europe, few data regarding the characteristics of EGFR exon 20 insertion (20ins) mutations in non-small cell lung cancer (NSCLC) are available…”
Get full text

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study by Descourt, Renaud, Pérol, Maurice, Rousseau-Bussac, Gaëlle, Planchard, David, Mennecier, Bertrand, Wislez, Marie, Cadranel, Jacques, Cortot, Alexis Benjamin, Guisier, Florian, Galland, Loïck, Do, Pascal, Schott, Roland, Dansin, Éric, Arrondeau, Jennifer, Auliac, Jean-Bernard, Geier, Margaux, Chouaïd, Christos

“…Brigatinib is a next-generation ALK inhibitor (ALKi) that shows efficacy in ALK inhibitor naïve and post-crizotinib ALK+ advanced NSCLCs (aNSCLCs). The…”
Get full text

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC by Besse, Benjamin, Charrier, Mélinda, Lapierre, Valérie, Dansin, Eric, Lantz, Olivier, Planchard, David, Le Chevalier, Thierry, Livartoski, Alain, Barlesi, Fabrice, Laplanche, Agnès, Ploix, Stéphanie, Vimond, Nadège, Peguillet, Isabelle, Théry, Clotilde, Lacroix, Ludovic, Zoernig, Inka, Dhodapkar, Kavita, Dhodapkar, Madhav, Viaud, Sophie, Soria, Jean-Charles, Reiners, Katrin S., Pogge von Strandmann, Elke, Vély, Frédéric, Rusakiewicz, Sylvie, Eggermont, Alexander, Pitt, Jonathan M., Zitvogel, Laurence, Chaput, Nathalie

“…Dendritic cell-derived exosomes (Dex) are small extracellular vesicles secreted by viable dendritic cells. In the two phase-I trials that we conducted using…”
Get full text

Association between lung cancer somatic mutations and occupational exposure in never-smokers by Paris, Christophe, Do, Pascal, Mastroianni, Bénédicte, Dixmier, Adrien, Dumont, Patrick, Pichon, Eric, Chouaid, Christos, Coudert, Bruno, Foucher, Pascal, Fraboulet, Séverine, Locatelli-Sanchez, Myriam, Baize, Nathalie, Dansin, Eric, Moreau, Lionel, Vincent, Michel, Missy, Pascale, Morin, Franck, Moro-Sibilot, Denis, Couraud, Sébastien

“…Occupational exposure constitutes a common risk factor for lung cancer. We observed molecular alterations in 73% of never-smokers, 35% of men and 8% of women…”
Get full text

Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice by Jamme, Philippe, Descarpentries, Clotilde, Gervais, Radj, Dansin, Eric, Wislez, Marie, Grégoire, Valérie, Richard, Nicolas, Baldacci, Simon, Rabbe, Nathalie, Kyheng, Maeva, Kherrouche, Zoulika, Escande, Fabienne, Copin, Marie Christine, Cortot, Alexis B.

“…Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have shown efficacy in the treatment of ALK-rearranged non–small-cell lung cancer (NSCLC),…”
Get full text

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial by Pannier, Diane, Adenis, Antoine, Bogart, Emilie, Dansin, Eric, Clisant-Delaine, Stéphanie, Decoupigny, Emilie, Lesoin, Anne, Amela, Eric, Ducornet, Sandrine, Meurant, Jean-Pierre, Le Deley, Marie-Cécile, Penel, Nicolas

“…The primary aim of this trial was to determine the recommended phase II dose (RP2D) of weekly paclitaxel (wP) administered in combination with oral metronomic…”
Get full text

Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study by Vannimenus, Corinne, Bricout, Hélène, Le Rouzic, Olivier, Mouawad, François, Chevalier, Dominique, Dansin, Eric, Rotsaert, Laurence, Lefebvre, Gautier, Cottencin, Olivier, Porte, Henri, Scherpereel, Arnaud, El Fahsi, Asmaa, Richard, Florence, Rolland, Benjamin

“…Active smoking at the time of diagnosis of a first head & neck (H&N) or lung cancer is associated with a worse cancer outcome and increased mortality. However,…”
Get full text

Report of eight recent cases of locally advanced primary pulmonary artery sarcomas: failure of Doxorubicin-based chemotherapy by Penel, Nicolas, Taieb, Sophie, Ceugnart, Luc, Dansin, Eric, Hoguet, Dominique, Vanseymortier, Luc, Lartigau, Eric

“…Case reports of primary pulmonary artery sarcomas are very rare. We described herein eight new cases diagnosed between December 2000 and December 2004. There…”
Get more information

Real-life experience of ceritinib in crizotinib-pretreated ALK + advanced non-small cell lung cancer patients by Cadranel, Jacques, Cortot, Alexis B, Lena, Hervé, Mennecier, Bertrand, Do, Pascal, Dansin, Eric, Mazieres, Julien, Chouaid, Christos, Perol, Maurice, Barlesi, Fabrice, Robinet, Gilles, Friard, Sylvie, Thiberville, Luc, Audigier-Valette, Clarisse, Vergnenegre, Alain, Westeel, Virginie, Slimane, Khemaies, Buturuga, Alexandru, Moro-Sibilot, Denis, Besse, Benjamin

“…Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase ( ) positive ( ) non-small cell lung cancer…”
Get full text

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report by Dansin, Eric, Carnot, Aurélien, Servent, Véronique, Daussay, Dorothée, Robin, Yves-Marie, Surmei-Pintilie, Ecaterina, Lauridant, Géraldine, Descarpentries, Clothilde, Révillion, Françoise, Delattre, Claire

“…Breast metastasis from other primary carcinoma is very rare and could be difficult to identify despite immunohistochemistry analysis. Breast metastasis from…”
Get full text

Asymptomatic Pelvic Metastasis from Thymic Carcinoma: A Case Report by Surmei-Pintilie, Ecaterina, Narducci, Fabrice, Farre, Isabelle, Kolesnikov-Gauthier, Helene, Boulanger, Thomas, Petit, Stephanie, Porte, Henri, Dansin, Eric

“…Thymic epithelial tumors are rare and often occur somewhere local. Metastatic sites of thymic carcinomas (Masaoka-Koga stage IVb) are mostly seen in the lung,…”
Get full text

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors by KUPPENS, Isa E. L. M, DANSIN, Eric, BOOT, Henk, FEGER, Celine, ASSADOURIAN, Sylvia, BONNETERRE, Maria-Edith, BEIJNEN, Jos H, SCHELLENS, Jan H. M, BONNETERRE, Jacques

“…Purpose: The aim of this study was to determine the daily maximum tolerated dose (MTD) and the dose-limiting toxicity for the following administration…”
Get full text

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial by Le Pechoux, Cecile, Pourel, Nicolas, Barlesi, Fabrice, Lerouge, Delphine, Antoni, Delphine, Lamezec, Bruno, Nestle, Ursula, Boisselier, Pierre, Dansin, Eric, Paumier, Amaury, Peignaux, Karine, Thillays, François, Zalcman, Gerard, Madelaine, Jeannick, Pichon, Eric, Larrouy, Anne, Lavole, Armelle, Argo-Leignel, Delphine, Derollez, Marc, Faivre-Finn, Corinne, Hatton, Matthew Q, Riesterer, Oliver, Bouvier-Morel, Emilie, Dunant, Ariane, Edwards, John G, Thomas, Pascal Alexandre, Mercier, Olaf, Bardet, Aurelie

“…In patients with non-small-cell lung cancer (NSCLC), the use of postoperative radiotherapy (PORT) has been controversial since 1998, because of one…”
Get full text